Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/056878external-prioritypatent/WO2009147212A1/en
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of TN2010000558A1publicationCriticalpatent/TN2010000558A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing sais capsule comprising asaid suspension formuation and to the packaging material for the finished capsule.
TNP2010000558A2009-06-042010-12-01Capsule pharmaceutical doage form comprising a suspension formulation of an indolinone derivative
TN2010000558A1
(en)
Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
(s)-n-(4-(4-acetylpiperazin-1-yl)benzyl)-n-(1-(4-benzylpiperazin-1-yl)-oxo-3-phenyl-propan-2-yl)acrylamide derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids